This site is intended for healthcare professionals

Aurinia announces publication of AURORA 1 phase III study results with Lupkynis for the treatment of lupus nephritis in The Lancet.

Read time: 1 mins
Last updated:11th May 2021
Published:11th May 2021
Aurinia Pharmaceuticals Inc. announced that The Lancet, an international, peer-reviewed medical journal, published the results of the Company’s Phase III AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN).
Condition: Lupus Nephritis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest